Table 2 Subgroup analyses of the association between hypertension and prostate cancer risk.
From: Hypertension and risk of prostate cancer: a systematic review and meta-analysis
Subgroup | Included studies | No. of cases | Pooled RR (95% CI) | P | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
Q | I2 (%) | P | |||||
Total | 21 | 1.08 (1.02–1.15) | 0.014 | 71.70 | 72.1 | <0.001 | |
Study design | |||||||
Cohort/nested case-control | 17 | 22,173 | 1.05 (0.99–1.11) | 0.115 | 50.30 | 68.2 | <0.001 |
Case-control | 4 | 2,193 | 1.49 (1.00–2.22) | 0.050 | 13.31 | 77.5 | 0.004 |
Geographical region | |||||||
America | 8 | 6,166 | 1.11 (0.97–1.27) | 0.121 | 14.70 | 52.4 | 0.040 |
Europe | 9 | 15,946 | 1.04 (0.97–1.11) | 0.245 | 37.13 | 78.5 | <0.001 |
Asia | 4 | 2,254 | 1.88 (1.04–3.38) | 0.036 | 9.38 | 68.0 | 0.025 |
Study quality | |||||||
High (NOS ≥ 7) | 9 | 20,072 | 1.16 (1.01–1.33) | 0.039 | 49.64 | 83.9 | <0.001 |
Low (NOS <7) | 12 | 4,294 | 1.06 (0.98–1.15) | 0.124 | 16.25 | 32.3 | 0.132 |
No. of cases | |||||||
≥1000 | 7 | 20,786 | 1.06 (0.95–1.20) | 0.303 | 32.81 | 81.7 | <0.001 |
<1000 | 14 | 3,580 | 1.15 (1.03–1.29) | 0.014 | 31.03 | 58.1 | 0.003 |
